Cargando…

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan

INTRODUCTION: Daprodustat is an approved treatment for anemia of chronic kidney disease (CKD) in Japan. METHODS: This post hoc analysis evaluated pooled safety data for daprodustat from 3 phase 3 Japanese studies in dialysis‐dependent and nondialysis patients with anemia of CKD. RESULTS: Median drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nangaku, Masaomi, Akizawa, Tadao, Nagakubo, Takashi, Yonekawa, Taeko, Kimura, Toshifumi, Endo, Yukihiro, Cobitz, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790622/ https://www.ncbi.nlm.nih.gov/pubmed/35312234 http://dx.doi.org/10.1111/1744-9987.13839

Ejemplares similares

Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients
por: Kanai, Hidetoshi, et al.
Publicado: (2021)

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
por: Ishii, Taisuke, et al.
Publicado: (2021)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease
por: Holdstock, Louis, et al.
Publicado: (2018)

An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018)

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial
por: Singh, Ajay K., et al.
Publicado: (2022)

A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis
por: Bailey, Christine K., et al.
Publicado: (2019)

Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
por: Meadowcroft, Amy M, et al.
Publicado: (2018)

Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
por: Tanaka, Tetsuhiro, et al.
Publicado: (2018)

Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function
por: Mahar, Kelly M., et al.
Publicado: (2022)

Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis
por: Zheng, Qiyan, et al.
Publicado: (2021)

An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat
por: Becker, Kimberly A., et al.
Publicado: (2017)

Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure
por: Caltabiano, Stephen, et al.
Publicado: (2019)

The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects
por: Caltabiano, Stephen, et al.
Publicado: (2018)

Daprodustat: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis
por: Fu, Zhangning, et al.
Publicado: (2022)

Daprodustat: A potential game-changer in renal anemia therapy—A perspective
por: Haider, Muhammad Usman, et al.
Publicado: (2023)

New measures against chronic kidney diseases in Japan since 2018
por: Fukui, Akira, et al.
Publicado: (2019)

Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies
por: Akizawa, Tadao, et al.
Publicado: (2021)

Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023)

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
por: Akizawa, Tadao, et al.
Publicado: (2022)

Estimating the causal effect of transient anemia status on renal and cardiovascular outcomes in community-dwelling patients in Japan at the beginning of impaired renal function using marginal structural modeling
por: Onozawa, Satoshi, et al.
Publicado: (2021)

Daprodustat for anaemia in patients with heart failure and chronic kidney disease: A randomized controlled study
por: Iso, Takashi, et al.
Publicado: (2022)

Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination
por: Mahar, Kelly M., et al.
Publicado: (2021)

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
por: Kato, Hideki, et al.
Publicado: (2017)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study
por: Kikuchi, Kan, et al.
Publicado: (2021)

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
por: Maruyama, Shoichi, et al.
Publicado: (2023)

Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
por: Hayashi, Terumasa, et al.
Publicado: (2020)

A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
por: Tuttle, Katherine R., et al.
Publicado: (2022)

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
por: Fujikawa, Ryo, et al.
Publicado: (2022)

Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
por: Itano, Seiji, et al.
Publicado: (2023)

Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB)
por: Sofue, Tadashi, et al.
Publicado: (2020)

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
por: Shigematsu, Takashi, et al.
Publicado: (2020)

Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study
por: Hasegawa, Takeshi, et al.
Publicado: (2018)

Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan
por: Shigematsu, Takashi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_27jjjnk5dhldok3tr4n3ppl6ei